# ORIC-944

Type: Technology

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/oric-944
Canonical HTML page: https://gethealthbrief.com/entity/oric-944

## Recent coverage (1 stories)

### Tarsus and ORIC 2025 Results: Commercial Scaling vs. Clinical Discipline
2026-02-23 22:49:02 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Tarsus Pharmaceuticals exceeded revenue expectations with $151.6 million in Q4 2025, driven by the commercial expansion of XDEMVY, while ORIC Pharmaceuticals demonstrated clinical-stage fiscal discipline with a narrowed quarterly loss. These results highlight the divergent financial profiles of commercial-stage specialty pharma versus pipeline-focused oncology developers.
Full story: https://gethealthbrief.com/story/tarsus-oric-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.